Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $82,636.42 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 2,357 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $35.06, for a total transaction of $82,636.42. Following the completion of the transaction, the director now owns 190,939 shares of the company’s stock, valued at approximately $6,694,321.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Dirk Kersten also recently made the following trade(s):

• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.32, for a total transaction of $1,442,150.92.
• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95.

Dyne Therapeutics Trading Down 2.3 %

NASDAQ DYN opened at $33.83 on Monday. The firm’s fifty day moving average price is $40.26 and its two-hundred day moving average price is $33.93. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $47.45. The firm has a market capitalization of $2.96 billion, a P/E ratio of -8.52 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently modified their holdings of the stock. RA Capital Management L.P. bought a new position in shares of Dyne Therapeutics in the first quarter valued at about $140,666,000. Vanguard Group Inc. grew its stake in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after acquiring an additional 1,110,629 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Dyne Therapeutics by 23,512.0% in the first quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after acquiring an additional 2,663,910 shares in the last quarter. Artal Group S.A. grew its stake in shares of Dyne Therapeutics by 24.6% in the first quarter. Artal Group S.A. now owns 1,517,960 shares of the company’s stock valued at $43,095,000 after acquiring an additional 300,000 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Dyne Therapeutics by 10.4% in the second quarter. Federated Hermes Inc. now owns 1,215,112 shares of the company’s stock valued at $42,881,000 after acquiring an additional 114,888 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Morgan Stanley boosted their price objective on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 9th. Guggenheim boosted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.40.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.